252 related articles for article (PubMed ID: 29564982)
41. QSAR analysis of thiolactone derivatives using HQSAR, CoMFA and CoMSIA.
Sainy J; Sharma R
SAR QSAR Environ Res; 2015; 26(10):873-92. PubMed ID: 26524489
[TBL] [Abstract][Full Text] [Related]
42. Theoretical studies on pyrimidine substituent derivatives as dual inhibitors of AP-1 and NF-kappaB.
Qian L; Liao SY; Huang ZL; Shen Y; Zheng KC
J Mol Model; 2010 Jun; 16(6):1139-50. PubMed ID: 19943176
[TBL] [Abstract][Full Text] [Related]
43. Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors.
Ul-Haq Z; Effendi JS; Ashraf S; Bkhaitan MM
J Mol Graph Model; 2017 Jun; 74():379-395. PubMed ID: 28499271
[TBL] [Abstract][Full Text] [Related]
44. Exploring the structure requirement for PKCθ inhibitory activity of pyridinecarbonitrile derivatives: an in silico analysis.
Li Y; Hao M; Ren H; Zhang S; Wang X; Ma M; Li G; Yang L
J Mol Graph Model; 2012 Apr; 34():76-88. PubMed ID: 22306416
[TBL] [Abstract][Full Text] [Related]
45. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
46. Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.
Keretsu S; Bhujbal SP; Cho SJ
J Biomol Struct Dyn; 2021 Feb; 39(3):753-765. PubMed ID: 31916502
[TBL] [Abstract][Full Text] [Related]
47. Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis.
Wang F; Ma Z; Li Y; Wang J; Wang Y
J Mol Model; 2012 Jul; 18(7):3227-42. PubMed ID: 22246285
[TBL] [Abstract][Full Text] [Related]
48. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
49. Identification of the naphthoquinone derivative inhibitors binding site in heat shock protein 90: an induced-fit docking, molecular dynamics and 3D-QSAR study.
Godoy-Castillo C; Bravo-Acuña N; Arriagada G; Faunes F; León R; Soto-Delgado J
J Biomol Struct Dyn; 2021 Oct; 39(16):5977-5987. PubMed ID: 32799638
[TBL] [Abstract][Full Text] [Related]
50. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
51. Binding site analysis of CCR2 through in silico methodologies: docking, CoMFA, and CoMSIA.
Kothandan G; Gadhe CG; Madhavan T; Cho SJ
Chem Biol Drug Des; 2011 Jul; 78(1):161-74. PubMed ID: 21294847
[TBL] [Abstract][Full Text] [Related]
52. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
53. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
54. Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one derivatives as potential Hsp90 inhibitors.
Musso L; Cincinelli R; Giannini G; Manetti F; Dallavalle S
Chem Biol Drug Des; 2015 Nov; 86(5):1030-5. PubMed ID: 25855505
[TBL] [Abstract][Full Text] [Related]
55. Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors.
Itteboina R; Ballu S; Sivan SK; Manga V
Comput Biol Chem; 2016 Oct; 64():33-46. PubMed ID: 27244086
[TBL] [Abstract][Full Text] [Related]
56. Structural features of falcipain-3 inhibitors: an in silico study.
Wang J; Li F; Li Y; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2296-310. PubMed ID: 23765034
[TBL] [Abstract][Full Text] [Related]
57. Molecular design of anticancer drug leads based on three-dimensional quantitative structure-activity relationship.
Huang XY; Shan ZJ; Zhai HL; Li LN; Zhang XY
J Chem Inf Model; 2011 Aug; 51(8):1999-2006. PubMed ID: 21755987
[TBL] [Abstract][Full Text] [Related]
58. Quantitative structure-activity relationship studies of mushroom tyrosinase inhibitors.
Xue CB; Luo WC; Ding Q; Liu SZ; Gao XX
J Comput Aided Mol Des; 2008 May; 22(5):299-309. PubMed ID: 18256890
[TBL] [Abstract][Full Text] [Related]
59. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.
Kim HH; Hyun JS; Choi J; Choi KE; Jee JG; Park SJ
Sci Rep; 2018 Jan; 8(1):368. PubMed ID: 29321504
[TBL] [Abstract][Full Text] [Related]
60. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
